Printer friendly version Share

News Release

Certain Factors May Predict Lung Cancer Patients’ Response to Chemotherapy

11 January 2018 Wiley

In a retrospective analysis of 73 lung squamous cell carcinoma patients treated with the chemotherapy regimen of gemcitabine plus cisplatin, higher body mass index and younger age were linked with longer progression-free survival, the length of time that a patient lives with cancer but it does not get worse. Patients with better response to treatment and higher body mass index had longer overall survival in the Thoracic Cancer analysis.

“Patients’ clinical pathological characteristics may be used to predict the therapeutic efficacy of chemotherapy and survival,” the authors wrote.

Elhuyar with Basque New Cambridge millet TON logo eNEWS ad FNSF ad New Norwegian logo